Alkem Laboratories Limited — Q3 FY25
Alkem reported Q3 FY25 revenue of INR 3,374 crore (+1.5% YoY) and EBITDA margin of 22.5% (+7.3% YoY), driven by cost optimization and focus on higher-margin offerings.
bullish
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q2 FY25
Domestic revenue growth of 8-9% for FY25
Management maintains full-year domestic growth guidance of 8-9%, with Q4 expected to be particularly strong.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q2 FY25
EBITDA margin improvement of ~100bps to 18.5-19% for FY25
Full-year EBITDA margin expected to be 18.5-19%, driven by cost controls and product mix improvement.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q2 FY25
US business flattish to mid-single-digit erosion for FY25
US revenue expected to decline flattish to mid-single-digit for the full year, with H2 performance better than H1.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q2 FY25
Enzyme plant commissioning by Q4 FY25 or Q1 FY26
The US biologic CDMO plant is expected to begin production by Q4 FY25 or Q1 FY26, with break-even targeted in the first year.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1